| Literature DB >> 15566582 |
Michael Eddleston1, Andrew Dawson, Lakshman Karalliedde, Wasantha Dissanayake, Ariyasena Hittarage, Shifa Azher, Nick A Buckley.
Abstract
Severe organophosphorus or carbamate pesticide poisoning is an important clinical problem in many countries of the world. Unfortunately, little clinical research has been performed and little evidence exists with which to determine best therapy. A cohort study of acute pesticide poisoned patients was established in Sri Lanka during 2002; so far, more than 2000 pesticide poisoned patients have been treated. A protocol for the early management of severely ill, unconscious organophosphorus/carbamate-poisoned patients was developed for use by newly qualified doctors. It concentrates on the early stabilisation of patients and the individualised administration of atropine. We present it here as a guide for junior doctors in rural parts of the developing world who see the majority of such patients and as a working model around which to base research to improve patient outcome. Improved management of pesticide poisoning will result in a reduced number of suicides globally.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15566582 PMCID: PMC1065055 DOI: 10.1186/cc2953
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
An observation chart recording the initial atropinisation of an organophosphorus-poisoned patient
| Time | Heart rate >80 | Clear lungs | Pupil size | Dry axilla | Syst. BP >80 mmHg | Bowel sounds (A/D/N/I) | Confused | Fever (>37.5°C) | Atropine infusion | Bolus given? |
| 22.30 | 90/60 | I | No | No | 2.4 mg | |||||
| 22.35 | 90/60 | I | No | No | 4.8 mg | |||||
| 22.40 | 82 | Yes | 110/60 | N | No | No | 4 mg | |||
| 22.50 | 100 | 2 mm | Yes | - | D | No | No | 2 mg | ||
| 23.00 | 105 | Clear | 3 mm | Yes | - | D | No | No | 2 mg/h | Infusion |
| 23.15 | 105 | Clear | 3–4 mm | Yes | - | D | No | No | 2 mg/h | Infusion |
| 23.32 | 102 | Clear | 3–4 mm | Yes | - | D | No | No | 2 mg/h | Infusion |
| 00.30 | 98 | Clear | 3–4 mm | Yes | 110/60 | D | No | No | 2 mg/h | Infusion |
| 01.30 | 85 | Clear | 3–4 mm | Yes | - | D | No | No | 2 mg/h | Infusion |
| 02.30 | 3–4 mm | Yes | - | N/D | No | No | 2 mg | |||
| 02.35 | 96 | Clear | 3–4 mm | Yes | - | D | No | No | 2.4 mg/h | Infusion |
| 02.45 | 98 | Clear | 3–4 mm | Yes | - | D | No | No | 2.4 mg/h | Infusion |
| 04.00 | 102 | Clear | 3–4 mm | Yes | - | D | No | No | 2.4 mg/h | Infusion |
Atropinisation was reached at 23.00, 30 min after the first atropine dose was given; a total of 13.4 mg of atropine was required. After 10 min, doubling doses were no longer used because there was a clear response to therapy with the pulse climbing above 80 beats/min and the chest sounding better. After a further 1.5 hours, the pulse rate started to drop but it was not until it had dropped below 80 beats/min and wheeze had become audible in the chest that another 2 mg bolus was given to atropinise the patient again. The atropine infusion rate was also increased and the patient remained stable for the next few hours.
A/D/N/I, absent/decreased/normal/increased; creps, crepitations; syst. BP, systolic blood pressure. Clinical features in bold type indicate that atropine is required. Dashes indicate that no BP reading was taken.
Target end-points for atropine therapy
| Clear chest on auscultation with no wheeze |
| Heart rate >80 beats/min |
| Pupils no longer pinpoint |
| Dry axillae |
| Systolic blood pressure >80 mmHg |
Notes:
1. The aim of atropine therapy is to clear the chest and reach the end-points for all five parameters.
2. There is no need to aim for a heart rate of 120–140 beats/min. This suggests atropine toxicity rather than simple reversal of cholinergic poisoning. Such high heart rates will cause particularly severe complications in older patients with pre-existing cardiac disease – myocardial infarctions may result. However, tachycardias are also caused by hypoxia, agitation, alcohol withdrawal, pneumonia, hypovolaemia, and fast oxime administration. Tachycardias are not a contraindication for atropine if other features suggest under-atropinisation.
3. Aspiration will commonly result in focal crepitations. Attempt to distinguish such crepitations from the more general crepitations of bronchorrhoea.
4. Splashes of organophosphorus into the eye will produce intense miosis that may not respond to atropine therapy. However, symmetrical miosis is likely to be due to systemic effects of the ingested pesticide.
Markers used to assess atropine toxicity
| Confusion |
| Pyrexia |
| Absent bowel sounds (Urinary retention) |
Notes:
Many factors can cause confusion and pyrexia. However, confusion and/or pyrexia in the absence of bowel sounds suggests that they are due to atropine toxicity and will respond to a reduction in the rate of atropine administration.
Alcohol withdrawal, requiring benzodiazepine therapy, must be considered in poisoned patients who are confused.
Control pyrexia as soon as possible; conditions causing pyrexia include agitation from alcohol withdrawal or atropine toxicity, atropine-induced failure to sweat, and high ambient temperature. Active cooling of the patient with fan and water-soaked towels must be a priority because they are at risk of hyperthermia-induced cardiac arrest. Most ill patients will be catheterised after resuscitation to observe urinary output. Urinary retention can therefore not then be used as a marker of toxicity.